Missing: Amicus Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Amicus Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Amicus Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Amicus Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Amicus Therapeutics Patents
Amicus Therapeutics has filed 175 patents.
EC 3.2.1, Excipients, Food additives, Dosage forms, Calcium compounds
EC 3.2.1, Excipients, Food additives, Dosage forms, Calcium compounds
Latest Amicus Therapeutics News
Jan 12, 2023
JPM 23 Roundup – 3 Biotechs with Philadelphia Ties Present at JP Morgan Healthcare Conference Numerous biopharma companies and organizations presented at the JP Morgan Healthcare conference held this week in San Francisco. Three with either headquarters in Philadelphia or ties to the area, were of note for their overview of 2022 and their outlook for 2023 and beyond. Here’s a look at presentations by Amicus Therapeutics, Avantor, and Jazz Pharmaceuticals. Amicus Therapeutics Bradley Campbell, president and CEO of Philadelphia-based Amicus Therapeutics presented an overview of the company on Monday, January 9. The company focuses on next-generation therapeutics for people living with rare and orphan diseases. The primary focus was on two drugs, Galafold, on the market for Fabry Disease, and AT-GAA, under regulatory review in several countries for Pompe Disease. Fabry Disease is an inherited lysosomal storage disease, which can cause life-threatening heart and kidney problems. Pompe Disease is an inherited and often fatal lysosomal storage disease that disables the heart and skeletal muscles. Galafold demonstrated a 12-17% revenue growth in 2022, bringing in $329 million. Amicus is also expecting multiple reviews and launches of AT-GAA this year. “I think that puts Amicus in a relatively unique position in the mid-cap biotech space with two products with $1.5 to $2 billion peak revenue combined,” Campbell said in the presentation. “All that with a very healthy balance sheet.” Campbell provided an overview of 2022, which had several milestones. These included Galafold operational revenue growth of 16%, positive long-term data from Phase I/II trials of AT-GAA in Pompe disease, and a positive CHMP opinion for Pombiliti in late-onset Pompe Disease. Pombiliti is a long-term enzyme replacement therapy for use in combination with the enzyme stabilizer miglustat (Janssen’s Zavesca) for late-onset Pompe disease. The company’s strategic priorities for 2023 are to sustain double-digit Galafold revenue growth of 12-17%, pick up approvals for AT-GAA from the FDA, European Medicines Agency (EMA), and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) with subsequent launches. It also plans to advance its best-in-class, next-generation Fabry and Pompe pipeline while maintaining a strong path to profitability. “We think 2023 will be a transformative year for Amicus, and we’re eager to execute across those strategic priorities,” Campbell said. Avantor Michael Stubblefield, Radnor, Pa.-based Avantor’s president and CEO presented an overview of the company. The company describes itself as a “leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies and applied materials industries.” Or as the company and Stubblefield proclaim, “setting science in motion to better the world.” Stubblefield noted that 85% of the company’s revenue is recurring. Of their business, 55% is related to biopharma, 10% to healthcare, 10% to education and government, and 25% to advanced technology and applied materials. “The similarities are high regulatory oversight and complex development processes,” Stubblefield said, with a “common product portfolio and significant supply chain networks.” Avantor’s four end markets represent a total addressable market of more than $80 billion. The company operates 30 manufacturing sites, more than 50 distribution locations, and 13 innovation centers. Its organic revenue growth is at 4-6% with about a 37% CAGR from 2019 to 2022 and about 2.5 times growth over the same period. Avantor has almost doubled its laboratory industry growth and demonstrated a “four-fold increase in bioproduction customers compared to a few years ago,” Stubblefield said. On Monday, January 9, Avantor inked a multi-year supply and services agreement with Somerset, NJ-based Catalent to supply a broad variety of laboratory supplies, clinical and production products, and services. Stubblefield concluded that Avantor “demonstrated we can execute in a dynamic environment and our core business remains quite strong. As I head into 2023 and beyond, we are well-positioned for continued high levels of performance.” Jazz Pharmaceuticals Bruce Cozadd, chairman and CEO of Jazz presented a company overview and strategic vision on January 9. Jazz has corporate headquarters in Dublin, with offices in Philadelphia, Palo Alto and Carlsbad, California, Vancouver, British Columbia, and Mississauga, Ontario. Cozadd noted that during 2022 Jazz “improved the lives of more patients and had strong topline growth.” The company focuses on neuroscience and oncology. Its neuroscience portfolio includes Epidiolex, Sativex, Xyrem and Xywav. Its oncology drugs include Defitelio, Rylaze, Vyxeos and Zepzelca. Cozadd said that for 2022, Jazz “will achieve total revenue guidance as well as guidance for both neuroscience and oncology.” In 2019, the company brought in $2.2 billion in revenue, and expects to hit the 2022 guidance of $3.6-$3.7 billion. They are planning to achieve $5 billion in revenue by 2025. Cozadd noted that “they expect to meet the 2022 target of 60-65% of net product sales from new products. All of this means we have the financial strength to continue to invest in sustainable growth and enhanced value creation.” Cozadd’s presentation focused largely on the company’s Vision 2025, which has three pillars: commercial, pipeline, and operational excellence. For their commercial capabilities, Cozadd noted, “We think our capabilities across commercial and R&D, along with our structural flexibility positions us as a partner of choice. We do believe this is a very favorable environment for companies looking to add new and interesting assets.” In terms of the pipeline, Jazz added three new molecules in 2022 by way of corporate development, filed four Investigational New Drug (IND) applications, and expects “multiple more this year,” according to Cozadd. They also launched seven clinical trials. For the third pillar, operational excellence, Jazz has $0.9 billion in cash, cash equivalents, and investments, $0.5 billion in an undrawn revolving credit facility, and is expecting several billion in cash flow through 2025. “With our track record of delivering top- and bottom-line growth; with our focus on excellence; with the investment we’re making across commercial, across R&D, across corporate development, we think we are very well positioned to achieve Vision 2025,” Cozadd said. About the Author
Amicus Therapeutics Frequently Asked Questions (FAQ)
When was Amicus Therapeutics founded?
Amicus Therapeutics was founded in 2002.
Where is Amicus Therapeutics's headquarters?
Amicus Therapeutics's headquarters is located at 1 Cedar Brook Drive, Cranbury.
What is Amicus Therapeutics's latest funding round?
Amicus Therapeutics's latest funding round is PIPE.
How much did Amicus Therapeutics raise?
Amicus Therapeutics raised a total of $146M.
Who are the investors of Amicus Therapeutics?
Investors of Amicus Therapeutics include Novo Ventures, Radius Ventures, New Enterprise Associates, Frazier Healthcare Partners, Canaan Partners and 7 more.
Who are Amicus Therapeutics's competitors?
Competitors of Amicus Therapeutics include Noveome Biotherapeutics, NGM Biopharmaceuticals, Motif BioSciences, Zyngenia, VirxSys and 12 more.
Compare Amicus Therapeutics to Competitors
Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.
Amrita Therapeutics develops drugs that combat public health threats of the 21st century with fewer side-effects and at an cost. Amrita Therapeutics therapies and cures will treat cervical cancer, CNS disorders, HIV/AIDS, malaria and/or tuberculosis by designing the products of bacteria to defend the human body against more than one disease simultaneously, utilizing or interfering in multiple pathways or mechanisms.
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
Alethia BioTherapeutics is a biotechnology company that develops monoclonal antibody therapeutics to clinically relevant targets identified using its STAR discovery technology.
Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.
Noveome Biotherapeutics is regenerative medicine company focused on the research, development and clinical use of its technology platform, derived from human placental cells. This platform provides a new approach to tissue regeneration and repair in a wide range of medical conditions. Noveome's technology platform is derived from a population of cells isolated from full-term placental tissue that is normally discarded following delivery of a baby. There is no interruption in the development of the baby to procure this tissue.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.